2014-10-27 08:30:00 CET

2014-10-27 08:30:02 CET


REGULATED INFORMATION

English Finnish
Biohit Oyj - Total number of voting rights and capital

Biohit Oyj B-shares Subscribed with Stock Options II 2013


Biohit Oyj Stock Exchange Release October 27, 2014 at 9:30 a.m. local time (EET)

A total number of 50,000 new Biohit Oyj B-shares have been subscribed for with
stock options II 2013 during October 8, 2014. These shares have been entered
into the trade register on October 27, 2014, as of which date the new shares
will establish equal shareholder rights with the company's existing B-shares.
Public trading is expected to begin on NASDAQ OMX Helsinki as of October 28,
2014 together with the existing B-shares. 

The share subscription price was EUR 2.2766 per share with stock options II
2013. The entire subscription price of EUR 113,830 will be credited to the
reserve for invested non-restricted equity, and the company share capital
remains unchanged. The shares have no nominal value. 

After the subscription the number of all Biohit Oyj's shares will rise into
14,080,593 shares (14,030,593) and B-shares will rise into 11,105,093 shares
(11,055,093). The new shares will correspond to a percentage of 0.4% of Biohit
Oyj's total number of shares and 0.07% of the voting rights after registration. 

The share subscription period with stock options II 2013 began on July 1, 2013
and will end June 30, 2015. The option schemes are based on the Biohit Oyj
board resolution of June 19, 2013 and the Annual General Meeting authorization
of April 13, 2011. The terms and conditions of the option schemes with
additional information are available on Biohit Oyj website at
www.biohithealthcare.com. 


Additional information:

CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com


Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit's
mission is “Innovating for Health” - we produce innovative products and
services to promote research and early diagnosis. Biohit is headquartered in
Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B
share (BIOBV) is quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare
group. www.biohithealthcare.com